Schilling, W., Jittamala, P., Watson, J., Boyd, S., Luvira, V., Siripoon, T., . . . Group, P. C. (2023). Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): An open-label, phase 2, randomised, controlled, adaptive trial. Elsevier.
Chicago Style (17th ed.) CitationSchilling, WHK, et al. Antiviral Efficacy of Molnupiravir Versus Ritonavir-boosted Nirmatrelvir in Patients with Early Symptomatic COVID-19 (PLATCOV): An Open-label, Phase 2, Randomised, Controlled, Adaptive Trial. Elsevier, 2023.
MLA引文Schilling, WHK, et al. Antiviral Efficacy of Molnupiravir Versus Ritonavir-boosted Nirmatrelvir in Patients with Early Symptomatic COVID-19 (PLATCOV): An Open-label, Phase 2, Randomised, Controlled, Adaptive Trial. Elsevier, 2023.